Structural Heart Devices Market Size & Share 2026-2035

Structural Heart Devices Market Size

The structural heart devices market was valued at USD 19.0 billion in 2025, is projected to advance to USD 20.9 billion in 2026, is expected to expand at an 8.4% CAGR (2026–2035), and is anticipated to reach USD 43.02 billion by 2035.

The structural heart devices market is being reshaped by the migration of valve replacement, repair, and appendage-closure care toward catheter-based treatment pathways. An aging patient population, broader clinical indications, and more refined imaging and delivery platforms are widening procedure eligibility, although the pace of adoption remains tied to specialist capacity, reimbursement design, and care-site readiness.

Structural Heart Devices Market Trends, Growth Drivers & GMI Forecast Outlook

Clinical demand is expanding beyond the early high-risk cohorts that established transcatheter structural heart care. The forecast is supported by growing diagnosis and procedural eligibility, but conversion of clinical need into device demand depends on trained heart teams, center accreditation, payer coverage, and the commercialization of newer mitral and tricuspid platforms.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Cardiovascular disease remains the leading cause of death globally, accounting for 19.8 million deaths in 2022, or approximately 32% of all deaths worldwide ^{[2]World Health Organization. "Cardiovascular Diseases (CVDs)." who.int}. Within structural heart care, the commercial effect is not limited to prevalence: earlier diagnosis, referral pathways, and multidisciplinary assessment determine whether valve disease, septal defects, or atrial appendage-related stroke risk converts into an intervention. This favors systems that can identify patients before symptoms become prohibitive and move them efficiently into specialist evaluation.

TAVR has provided the operational model for broader transcatheter adoption. As heart teams gain procedural confidence, hospitals can extend established imaging, anesthesia, catheterization, and follow-up infrastructure into mitral, tricuspid, and closure therapies. Product innovation reinforces that transition by improving navigability, sizing precision, sealing performance, and access in challenging anatomy. The resulting opportunity is both procedural and replacement-driven: newer platforms can treat additional patients while creating revision demand within an expanding installed base.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Structural heart care remains capacity-sensitive because favorable outcomes depend on more than implant availability. Programs must maintain coordinated imaging, interventional, surgical, anesthesia, and post-procedure capabilities, while physicians require sustained case exposure to progress beyond the learning curve. This particularly constrains diffusion of mitral and tricuspid interventions, where patient selection and intraprocedural imaging remain more demanding than in mature aortic programs.

Payer design can also slow adoption even when clinical rationale is established. For LAAC, coverage requirements and procedural economics affect whether hospitals prioritize program expansion, dedicate staff to registry obligations, or invest in outpatient pathways. Regulatory review adds another timing constraint: evidence generation, label expansion, reimbursement adoption, and provider readiness do not necessarily occur in sequence. These delays make commercial realization less immediate for emerging structural heart categories than clinical trial progress alone might suggest.

Structural Heart Devices Market Segment Analysis

By Product

Transcatheter heart valves generated USD 8.17 billion in 2025 and are projected to represent 49.0% of the structural heart devices market by 2035. Their position reflects the established role of transcatheter aortic valve replacement and the gradual broadening of transcatheter treatment across mitral, tricuspid, and pulmonary valve disease. Device selection increasingly turns on anatomy-specific sizing, delivery profile, repositionability, durability expectations, and compatibility with valve-in-valve treatment, making platform breadth a central competitive consideration.

Surgical heart valves represented 21.0% of market revenue in 2025 and are projected to generate USD 7.31 billion by 2035. Surgical replacement remains clinically necessary for patients requiring concomitant cardiac surgery, those with anatomy outside transcatheter labeling, and cohorts in which durability or direct operative access remains decisive. The category is therefore evolving toward a more selective role rather than being displaced outright, with minimally invasive and sutureless approaches helping preserve its relevance.

Occluders & delivery systems accounted for 20.0% of the market in 2025 and are projected to expand at an 8.8% CAGR (2026–2035). Demand is supported by LAAC, septal closure, and the enabling delivery infrastructure required for complex catheter-based procedures. Adoption depends heavily on referral networks for atrial fibrillation patients, physician confidence in stroke-prevention alternatives, and the ability of providers to absorb administrative and follow-up requirements.

Annuloplasty rings generated USD 950 million in 2025 and are projected to represent 4.0% of the market by 2035. Their continued role is tied to repair-first treatment strategies for suitable mitral and tricuspid anatomy, particularly where surgical or minimally invasive repair can preserve native valve function. Growth is likely to remain measured because rings are linked to operative pathways that face increasing competition from transcatheter repair and replacement technologies.

By Procedure

TAVR generated USD 8.93 billion in 2025 and is projected to represent 45.0% of the structural heart devices market by 2035. The procedure remains the commercial anchor of the market because it has established referral patterns, standardized heart-team workflows, and broad clinical familiarity across risk categories. Its future mix will be influenced by treatment of younger patients, valve-in-valve cases, lifetime management considerations, and the ability of manufacturers to differentiate on hemodynamics, access, and coronary reaccess.

SAVR represented 17.0% of the market in 2025 and is projected to generate USD 5.59 billion by 2035. Conventional surgery retains a durable role in patients with bicuspid disease, complex multivalve disease, concomitant coronary or aortic surgery needs, and clinical profiles requiring direct surgical correction. The category's outlook is consequently shaped less by broad conversion to transcatheter treatment than by case-mix complexity and the capacity of surgical programs to maintain differentiated valve-replacement pathways.

TMVR is projected to generate USD 3.44 billion by 2035 and expand at a 13.1% CAGR (2026–2035). The procedure addresses a difficult treatment population in which severe mitral regurgitation, annular calcification, prior surgery, or anatomy unsuitable for repair can leave limited options. Commercial scaling will require dependable patient selection, imaging-led planning, procedural reproducibility, and evidence that supports reimbursement and physician confidence beyond early specialist adopters.

LAAC generated USD 1.90 billion in 2025 and is projected to represent 10.0% of the market by 2035. Its growth is linked to the need for nonpharmacologic stroke-risk management among selected atrial fibrillation patients, particularly those unable to sustain long-term anticoagulation. Procedure volume will depend on how cardiology and electrophysiology referral channels develop, as well as the extent to which coverage criteria and registry requirements enable broader hospital participation.

TMVr represented 9.5% of the market in 2025 and is projected to generate USD 5.16 billion by 2035. Edge-to-edge repair has established a differentiated place in treating degenerative and functional mitral regurgitation where a repair-based approach remains clinically appropriate. Continued expansion will rest on greater anatomic reach, improved leaflet-grasping performance, and the ability of structural heart programs to integrate repair and replacement options into a coherent treatment algorithm.

TTVr generated USD 665 million in 2025 and is projected to represent 5.0% of the market by 2035. The category addresses an historically underserved population for whom surgical treatment has often been delayed or avoided because of procedural risk. Its commercial trajectory will depend on whether earlier referral, dedicated imaging protocols, and practical treatment pathways turn recently available repair and replacement technologies into routine options at experienced centers.

By End Use

Hospitals represented 74.0% of structural heart device demand in 2025 and are projected to generate USD 29.26 billion by 2035. Hospitals remain the principal setting because complex valve and repair procedures require multidisciplinary teams, advanced imaging, surgical backup, and the ability to manage high-acuity cases. Their continued leadership will be reinforced by concentration of expertise, although mature programs may shift selected lower-complexity cases toward less intensive settings.

Ambulatory surgery centers generated USD 2.47 billion in 2025 and are projected to represent 18.0% of the market by 2035. ASC participation is linked to shorter-stay procedural models, favorable patient selection, and operating pathways that reduce post-procedure resource intensity without compromising safety. The transition will remain selective, as many structural heart procedures still require hospital-based infrastructure and immediate escalation capacity.

Cardiac catheterization laboratories represented 10.0% of demand in 2025 and are projected to expand at a 9.5% CAGR (2026–2035). These laboratories are increasingly relevant for percutaneous closure procedures and carefully selected valve interventions that can be performed under streamlined care models. Their contribution depends on institutional protocols, imaging integration, and the availability of experienced teams capable of managing complex cases without diluting procedural quality.

Structural Heart Devices Market Regional Analysis

North America Structural Heart Devices Market Analysis

The structural heart devices market in North America generated USD 9.12 billion in 2025 and is projected to represent 42.7% of the global market by 2035. The region benefits from established structural heart referral networks, advanced imaging capacity, and broad clinical experience with transcatheter valve and closure procedures. Its relative global weight is likely to moderate as emerging regions scale more rapidly, but its installed base, reimbursement infrastructure, and early adoption of successive device generations preserve its role as the largest commercial market.

United States

The United States generated USD 8.20 billion in 2025 and is projected to represent 38.4% of the global market by 2035. Deep penetration of TAVR programs across academic and community hospitals, along with established use of mitral repair and appendage closure platforms, supports demand. Future growth will depend on the commercial ramp of newer mitral and tricuspid technologies and on continued alignment among coverage policy, center accreditation, and patient referral.

Canada

Canada represented 4.8% of the global market in 2025 and is projected to generate USD 1.83 billion by 2035. Demand is concentrated in regional cardiac centers that have progressively integrated transcatheter treatment into established valve-care pathways. The market's expansion will be shaped by provincial funding decisions, capacity at specialist centers, and the pace at which new therapies are incorporated into publicly funded clinical practice.

Europe Structural Heart Devices Market Analysis

Europe represented 27.0% of the global market in 2025 and is projected to generate USD 10.87 billion by 2035. The region combines established structural heart research networks, broad procedural experience, and healthcare systems that support specialist-center adoption. Market development will vary by national reimbursement design and hospital capacity, but the installed base of valve programs provides a strong platform for expanding mitral, tricuspid, and closure procedures.

Germany

Germany generated USD 1.12 billion in 2025 and is projected to represent 5.6% of the global market by 2035. Its dense network of cardiac centers and high procedural familiarity support early uptake of structural heart innovation. The country remains an important reference market for manufacturers seeking clinical validation, physician training, and broader continental European adoption.

United Kingdom

The United Kingdom represented 5.4% of the global market in 2025 and is projected to generate USD 2.17 billion by 2035. Expansion is supported by the progressive incorporation of transcatheter procedures into commissioned care pathways and specialist-center networks. Access will continue to depend on capacity planning, referral efficiency, and the ability of NHS services to accommodate newer mitral and closure therapies alongside established valve programs.

France

France generated USD 770 million in 2025 and is projected to represent 3.8% of the global market by 2035. Its structural heart ecosystem is supported by active clinical research, experienced centers, and established valve-intervention practice. Incremental demand is expected to come from the integration of emerging mitral and tricuspid technologies into mature transcatheter treatment pathways.

Italy

Italy represented 3.8% of the global market in 2025 and is projected to generate USD 1.52 billion by 2035. Demand is concentrated at large regional cardiac centers, where transcatheter adoption is supported by specialist clinical expertise. Continued market development depends on reimbursement alignment, regional service capacity, and extension of advanced intervention capabilities beyond the best-established programs.

Spain

Spain represented 3.2% of the global market in 2025 and is projected to generate USD 1.30 billion by 2035. Established TAVR activity across accredited programs provides a foundation for broader mitral repair and LAAC utilization. Growth will increasingly be determined by deeper procedure volume at existing centers rather than widespread creation of entirely new structural heart programs.

Netherlands

The Netherlands represented 1.9% of the global market in 2025 and is projected to generate USD 761 million by 2035. Its academic medical-center concentration supports adoption of novel transcatheter platforms and high-complexity care. The market is positioned to remain innovation-led, with clinical research participation and specialist training serving as important channels for new technology uptake.

Asia Pacific Structural Heart Devices Market Analysis

Asia Pacific represented 20.0% of the global market in 2025 and is projected to generate USD 11.35 billion by 2035. The region's growth is supported by large aging populations, rising diagnosis of valve disease, expanding cardiac infrastructure, and increasing domestic and international device competition. Market development remains uneven, with leading urban centers advancing quickly while access outside major referral networks continues to constrain penetration.

China

China generated USD 1.33 billion in 2025 and is projected to represent 10.6% of the global market by 2035. A large patient population, growing cardiac intervention capacity, and expanding domestic device capabilities support demand. The scale of future opportunity will depend on broadening access beyond major cities, the evolution of reimbursement support, and competition between domestic platforms and global manufacturers.

Japan

Japan represented 5.0% of the global market in 2025 and is projected to generate USD 2.60 billion by 2035. Its mature hospital network and aging population support sustained demand for valve and closure therapies. Continued expansion will be driven by the ability of certified centers to integrate newer platforms while maintaining procedural quality in an established TAVR market.

India

India is projected to generate USD 1.24 billion by 2035 and expand at a 12.1% CAGR (2026–2035). Demand is supported by the coexistence of rheumatic and degenerative valve disease, increasing tertiary-care capacity, and wider commercial access to transcatheter technologies. Affordability, reimbursement depth, physician training, and concentration of advanced care in major cities will remain decisive factors in converting population need into device adoption.

South Korea

South Korea represented 1.8% of the global market in 2025 and is projected to generate USD 795 million by 2035. Academic centers and national health insurance coverage for eligible procedures provide a base for continued structural heart adoption. Future demand will be shaped by the introduction of newer mitral and tricuspid platforms and by evidence supporting their use in the local clinical setting.

Australia

Australia generated USD 285 million in 2025 and is projected to represent 1.4% of the global market by 2035. Its well-developed structural heart programs support continued TAVR utilization and gradual adoption of mitral repair and LAAC therapies. Growth is likely to remain concentrated in major cardiac centers that can sustain the imaging, procedural, and follow-up requirements of advanced interventions.

Latin America Structural Heart Devices Market Analysis

Latin America generated USD 570 million in 2025 and is projected to expand at a 10.6% CAGR (2026–2035). Rising cardiac procedure volumes, regulatory access to transcatheter platforms, and private-sector investment in catheterization infrastructure underpin demand. However, public-system funding gaps, uneven specialist capacity, and constrained reimbursement will continue to limit the pace of penetration outside leading urban hospitals.

Brazil

Brazil generated USD 257 million in 2025 and is projected to represent 1.6% of the global market by 2035. It is the region's principal structural heart market, supported by private hospital investment, growing access to transcatheter platforms, and demand associated with both rheumatic and degenerative valve disease. Broader adoption will depend on the extent to which procedure availability reaches beyond a limited group of high-capability centers.

Mexico

Mexico represented 0.9% of the global market in 2025 and is projected to generate USD 465 million by 2035. Demand is concentrated in major public institutions and private hospitals with structural heart expertise. Population aging, regulatory availability, and growth in privately funded care will support expansion, while variability in public funding and specialist access will remain material constraints.

Argentina

Argentina is projected to generate USD 232 million by 2035 and expand at a 10.4% CAGR (2026–2035). The market is supported by accredited centers serving both private-sector patients and those covered through social health insurance arrangements. Economic conditions, procurement capacity, and the availability of imported technologies will influence the speed at which transcatheter therapies become more broadly accessible.

Middle East & Africa Structural Heart Devices Market Analysis

Middle East & Africa represented 2.0% of the global market in 2025 and is projected to generate USD 900 million by 2035. Growth is centered on investment in advanced cardiac care within Gulf markets and selected tertiary centers in Africa. The regional opportunity is meaningful but remains bounded by differences in reimbursement, specialist availability, and access between urban referral systems and the broader population.

Saudi Arabia

Saudi Arabia represented 0.6% of the global market in 2025 and is projected to generate USD 270 million by 2035. Government-supported healthcare investment and tertiary cardiac programs provide a foundation for structural heart adoption. Further growth will depend on continued expansion of interventional cardiology capability, trained teams, and referral pathways for advanced valve and closure procedures.

UAE

The UAE generated USD 95 million in 2025 and is projected to represent 0.5% of the global market by 2035. Private healthcare investment and its role as a regional referral destination support demand for complex structural heart interventions. Program growth will be linked to continued center accreditation, physician recruitment, and the development of dependable cross-border referral channels.

South Africa

South Africa represented 0.4% of the global market in 2025 and is projected to generate USD 180 million by 2035. Demand is anchored in a limited number of tertiary cardiac centers, with private-sector access continuing to shape the market. Expansion will require broader specialist capacity and stronger funding pathways for advanced interventions beyond the most established urban programs.

Structural Heart Devices Market Share & Competitive Landscape

The structural heart devices market is concentrated, with key players including Edwards Lifesciences, Medtronic plc, Abbott, Boston Scientific Corporation, LivaNova PLC, AtriCure, Artivion (formerly CryoLife), BIOMERICS, BRAILE Biomédica, JenaValve Technology, Lepu Medical Technology, and NuMED Inc. The top five companies collectively accounted for approximately 71.6% of global market revenue in 2025. Market leadership is driven by clinical evidence, regulatory expertise, physician training capabilities, specialist commercial infrastructure, and the ability to support complex structural heart procedures across valve replacement, valve repair, closure, and appendage management applications.

Competitive intensity continues to increase as manufacturers expand beyond individual devices toward comprehensive structural heart platforms that combine advanced implant technologies, delivery systems, clinical support services, and long-term patient management solutions. Regulatory approvals, physician training, clinical outcomes data, and hospital adoption remain critical factors influencing competitive success within the market.

Recent Industry Developments

December 2025 - Edwards Lifesciences SAPIEN M3 FDA Approval: The U.S. Food and Drug Administration approved Edwards Lifesciences' SAPIEN M3 transcatheter mitral valve replacement system on December 23, 2025, as the first transseptal transcatheter therapy of its kind. The approval expands treatment options for selected patients with severe mitral regurgitation or mitral annular calcification who are unsuitable for surgery or transcatheter edge-to-edge repair ^{[6]Edwards Lifesciences. "FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy." edwards.com}. The development strengthens competition in mitral replacement and raises the importance of imaging, case selection, and delivery-system execution in defining commercial uptake.

September 2026 - Medtronic Strategic Investment in Pi-Cardia: Medtronic announced a strategic investment in Pi-Cardia to accelerate development and commercialization of leaflet-modification technologies for complex valve-in-valve TAVR. The agreement is intended to support treatment of patients at risk of coronary obstruction and preserve coronary access in challenging reintervention cases ^{[7]Medtronic. "Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR." news.medtronic.com}. The transaction highlights the growing strategic value of adjunct technologies that solve procedural limitations as the installed base of transcatheter valve recipients matures.